Floatz logo

FLUOXETINE

Autism

Icahn School of Medicine at Mount SinaiSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Autism cohort.

Asset / SponsorPhaseRating
Lurasidone
Sumitomo Pharma America, Inc.
Phase 3BB
Rapamycin
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 2B
Everolimus
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 2B
Sertraline
Holland Bloorview Kids Rehabilitation Hospital
Phase 2CCC
Cholesterol Suspension
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 1/2CCC
Opc-34712
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 1CC

Same molecule, other indications

FLUOXETINE is also rated in:

depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
anxiety disorderDormant
BBB
Indicative ·
74 / 100
View asset →
mood disorderDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →